Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05235074

OH2 Oncolytic Viral Therapy in Central Nervous System Tumors

A Clinical Study of Oncolytic Virus (OH2) Injection in the Treatment of Patients Undergoing Surgery After Recurrence of Central Nervous System Tumors

Sponsor: Binhui Biopharmaceutical Co., Ltd.

Conditions Central Nervous System Tumors

Interventions OH2 injection

Updated 7 times since 2022 Last updated: Jul 22, 2025 Started: Nov 16, 2021 Primary completion: Jun 16, 2026 Completion: Jun 16, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05235074, this PHASE1/PHASE2 trial focuses on Central Nervous System Tumors and remains actively recruiting participants. Sponsored by Binhui Biopharmaceutical Co., Ltd., it has been updated 7 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Aug 2025 — Present [monthly]

Recruiting PHASE1/PHASE2

Status: Unknown → Recruiting
Jul 2025 — Aug 2025 [monthly]

Unknown PHASE1/PHASE2

Status: Recruiting → Unknown
Sep 2024 — Jul 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Mar 2023 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2
Mar 2022 — Feb 2023 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Binhui Biopharmaceutical Co., Ltd.

Data source: Binhui Biopharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China